ArticleFrontiers in pediatrics2025
The clinical manifestation and diagnostic features of Kawasaki-like phenotypes in pediatric multisystem inflammatory syndrome: a comparative retrospective study in Ukraine.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kawasaki Disease in Canada: The Impact of the COVID-19 Pandemic.CJC pediatric and congenital heart disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical overlap syndrome between multisystem inflammatory syndrome in children (MIS-C) and Kawasaki disease (KD), particularly in the context of SARS-CoV-2 infection, presents diagnostic challenges. The presence of both complete and incomplete Kawasaki-like phenotypes (KLP) further complicates differentiation. This study aimed to analyze Kawasaki-like phenotype of MIS-C, its clinical features, and improve diagnostic accuracy, patient outcomes. Methods: A retrospective cohort study was conducted on 48 pediatric patients diagnosed with MIS-С between 2020 and 2022. All cases met the MIS-C diagnostic criteria established by the Council of State and Territorial Epidemiologists (2022) and were classified according to the American Heart Association Kawasaki disease criteria (2017). Patients were grouped as non-Kawasaki-like or Kawasaki-like MIS-C phenotypes, with the latter subdivided into complete and incomplete subtypes. Clinical and echocardiographic features were compared using appropriate statistical methods. Results: Among the 48 MIS-C cases analyzed, 22 patients (46%) met the Kawasaki disease criteria, equally divided between complete and incomplete Kawasaki-like phenotypes. btion was longest in the complete phenotype (9.7 days) and shortest in the incomplete phenotype (5.5 days). Patients with neurological involvement experienced longer febrile periods (8.3 vs. 5.4 days). All 100% patients with the complete phenotype exhibited neurological symptoms vs. 46% of incomplete cases. Half of the Kawasaki-like phenotype patients demonstrated echocardiographic abnormalities vs. 15% of non-Kawasaki-like (NKL); highest in the incomplete phenotype (91%) compared to 15% in non-Kawasaki-like and 9% in complete KLP. The highest incidence of coronary dilatation was recorded in the incomplete phenotype (73%) vs. 9% in the complete and 15% in the non-Kawasaki-like MIS-C. Discussion: Kawasaki-like MIS-C phenotypes display distinct clinical and cardiovascular profiles. Accurate phenotypic identification is crucial for risk stratification and optimizing patient management. Further research is necessary to refine classification criteria and establish effective long-term monitoring strategies for affected children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.